tbuckley/cabot-search huggingface dataset:
Honoring Patient Preferences in Initiation of Dialysis
Authors: Vishnu S. Potluri, Laura M. Dember, Peter P. Reese
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Vertical Transmission of C-Type Viruses: Their Presence in Baboon Follicular Oocytes and Tubal Ova2
Authors: S. S. Kalter, R. L. Heberling, G. C. Smith, M. Panigel, D. C. Kraemer, R. J. Helmke, A. Hellman
Journal: JNCI Journal of the National Cancer Institute (1975)

Journal Article Vertical Transmission of C-Type Viruses: Their Presence in Baboon Follicular Oocytes and Tubal Ova Get access S. S. Kalter, S. S. Kalter Search for other works by this author on: Oxford Academic PubMed Google Scholar R. L. Heberling, R. L. Heberling Search for other works by this author on: Oxford Academic PubMed Google Scholar G. C. Smith, G. C. Smith Search for other works by this author on: Oxford Academic PubMed Google Scholar M. Panigel, M. Panigel Search for other works by this author on: Oxford Academic PubMed Google Scholar D. C. Kraemer, D. C. Kraemer Search for other works by this author on: Oxford Academic PubMed Google Scholar R. J. Helmke, R. J. Helmke Search for other works by this author on: Oxford Academic PubMed Google Scholar A. Hellman A. Hellman Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 54, Issue 5, May 1975, Pages 1173–1176, https://doi.org/10.1093/jnci/54.5.1173 Published: 01 May 1975 Article history Received: 23 October 1974 Accepted: 03 January 1975 Published: 01 May 1975
Abstract 14762: Determinants of Treatment Seeking Delay in Older Adults With Acute Decompensated Heart Failure
Authors: Kristen A Sethares, Mary-Elizabeth Sosa, Paige Fisher, Barbara Riegel
Journal: Circulation (2013)

Background: Despite reports that persons with heart failure (HF) symptoms delay up to 7 days before seeking treatment, few studies have prospectively explored specific factors influencing treatment...
Donor and recipient parameters affecting 1-year follow-up after lung transplant: Padova experience
Authors: Elisabetta Balestro, Emanuela Rossi, Francesca Lunardi, Giuseppe Marulli, Monica Loy, Francesco Di Chiara, Fiorella Calabrese, Federico Rea
Journal: European Respiratory Journal (2011)

The critical shortage of donor lungs suitable for transplant significantly limits the number of potential recipients. Many questions regarding donor acceptability still remain unanswered. Regarding recipients, less is known about peri-operative factors affecting 1-year survival. To investigate how multiple risk factors influence short term survival we retrospectively reviewed clinical data of donors and their recipients, transplanted in our centre.  We collected data from donors (n=174, mean age 35.7+1.0) focusing on age, Body Mass Index (BMI), orotracheal intubation (OTI) duration, marginality, cause of death, tracheal secretions and selected clinical information from their recipients (n= 200, mean age 46.8+1.0): native disease, BMI, type of transplant, intensive care unit (ICU) stay and OTI duration.  Donor age, above 35 yrs, and overweight (BMI>25) were independent predictors of survival less 1 year (respectively p=0.004; p = 0.05). Instead OTI duration (> 3 days), marginality, death for traumatic/cardiovascular cause, presence of tracheal secretions did not affect survival (respectively p=0.73;p=0.92;p=0.40;p = 0.40; p=0.40). Concerning recipients, BMI between 18 to 20 (p=0.04) and age under 50yrs (p=0,005) predisposes to longer survival. Prolonged ICU stay (>20 days,p=0.007) and OTI duration (>3 days,p=0.00001) negatively affect short survival.  Our data suggest that some peri-operative donor characteristics do not affect short survival and might help maximize lung availability from donor pool. Recipient evaluation confirm how crucial is to reduce OTI duration which, in our study, have influenced 1year survival.
International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma.
Authors: G M Brodeur, R C Seeger, A Barrett, F Berthold, R P Castleberry, G D'Angio, B De Bernardi, A E Evans, M Favrot, A I Freeman
Journal: Journal of Clinical Oncology (1988)

Neuroblastoma is one of the most common tumors in childhood. However, it often has been difficult to compare clinical and laboratory studies of this disease due to a lack of uniform criteria for diagnosis, staging, and response. An international group of conferees addressed each of these issues and reached a consensus. Specific criteria for making a diagnosis of neuroblastoma are defined. A new neuroblastoma staging system is proposed that takes into account the most important elements of current but incompatible systems. Finally, criteria for response to treatment are standardized. The criteria proposed herein represent an international consensus of essentially every major pediatric oncology group or organization in the United States, Europe, and Japan. The staging system should be referred to as the International Neuroblastoma Staging System, and the response criteria as the International Neuroblastoma Response Criteria. Implementation of these criteria will greatly facilitate the comparison of clinical and laboratory studies by different groups and countries. Furthermore, these criteria should serve as a foundation on which future modifications or improvements can be based.
Primary large-cell lymphoma of the mediastinum.
Authors: A C Aisenberg
Journal: Journal of Clinical Oncology (1993)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1993.11.12.2291 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 8246017 Primary large-cell lymphoma of the mediastinum. A C AisenbergxA C AisenbergSearch for articles by this author https://doi.org/10.1200/JCO.1993.11.12.2291 First Page PDF © 1993 by American Society of Clinical Oncology
Diet, weight loss, and liver health in nonalcoholic fatty liver disease: Pathophysiology, evidence, and practice
Authors: Giulio Marchesini, Salvatore Petta, Riccardo Dalle Grave
Journal: Hepatology (2015)

Fatty liver accumulation results from an imbalance between lipid deposition and removal, driven by the hepatic synthesis of triglycerides and de novo lipogenesis. The habitual diet plays a relevant role in the pathogenesis of nonalcoholic fatty liver disease (NAFLD), and both risky (e.g., fructose) and protective foods (Mediterranean diet) have been described, but the contribution of excess calories remains pivotal. Accordingly, weight loss is the most effective way to promote liver fat removal. Several controlled studies have confirmed that an intense approach to lifestyle changes, carried on along the lines of cognitive‐behavior treatment, is able to attain the desired 7%‐10% weight loss, associated with reduced liver fat, nonalcoholic steatohepatitis (NASH) remission, and also reduction of fibrosis. Even larger effects are reported after bariatric surgery‐induced weight loss in NAFLD, where 80% of subjects achieve NASH resolution at 1‐year follow‐up. These results provide solid data to evaluate the safety and effectiveness of the pharmacological treatment of NASH. The battle against metabolic diseases, largely fueled by increased liver fat, needs a comprehensive approach to be successful in an obesiogenic environment. In this review, we will discuss the role of hepatic lipid metabolism, genetic background, diet, and physical activity on fatty liver. They are the basis for a lifestyle approach to NAFLD treatment. (H epatology 2016;63:2032‐2043)
Arterial infusion of Onyx-015: Response rate and survival among patients with metastatic colorectal cancer refractory to 5-fu
Authors: D. Sze, S. Freeman, T. R. Reid
Journal: Journal of Clinical Oncology (2004)

3067 Background: We conducted a phase II trial of hepatic artery infusion of Onyx-015 among patients with advanced colorectal cancer. This analysis is restricted to patients with documented progression on one or more 5-FU/leucovorin based regimens. The expected time to progression for patients receiving second-line therapy after failing 5-FU leucovorin is 3 to 4 months, the median survival is approximately 8 months and less than 1% of these patients achieve partial responses. Methods: All 24 patients included in this analysis were treated with 5-FU as first-line therapy and progressed on treatment. 79% (19/24) of the patients failed 2 or more regimens before entering the trial and 75% (18/24) of the patients received at least one additional 5-FU based regimen. 58% received Irinotecan, 17% received Oxaliplatin, 17% received Xeloda and 25% received an experimental therapy. Results: The median survival was 10.7 months and 17% of the patients were alive at 2 years. The median survival was shorter among patients whose tumors had mutations in the p53 gene and those who had failed treatment with Irinotecan. Radiographic analysis demonstrated that over one third of the patients developed transient tumor enlargement after the initial infusions with Onyx-015 followed by slow regression of the tumor masses. The median survival of the patients demonstrating this biphasic radiographic response was 19 months. Conclusion: The patients enrolled on the trial of arterial infusion of Onyx-015 were heavily pretreated; however, the median survival compares favorably with studies of patients failing only first-line therapy with a 5-FU based regimens. No dose-limiting toxicities were observed despite the administration of up to 8 arterial infusions. The biphasic tumor response noted on the CT scans suggests infection and inflammation of the tumor masses and is correlated with an improved survival. Standard radiographic response rate criteria may not accurately capture the clinical activity of biologic agents. These results suggest that Onyx-015 has activity among 5-FU refractory colorectal cancer and further clinical evaluation is warranted. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Onyx Onyx Pharmaceuticals Onyx
Rectal thermometer should be used for accurate temperature reading, analysis finds
Authors: J. Wise
Journal: BMJ (2015)

Most of the commonly used peripheral thermometers—those that are used under the arm or orally—do not accurately measure body temperature, a meta-analysis published in Annals of Internal Medicine has found.1 At extremes of body temperature, peripheral temperature measurements may be as much as 1-2°C higher or lower than actual body temperature, the study found.

The Canadian researchers said that doctors should consider using a central thermometer when the …
A Phase I-II Study of the Efficacy and Safety of Lenalidomide (LEN) Combined to Azacitidine (AZA) in Higher Risk MDS and AML with Del 5q - a Study By the Groupe Francophone Des Myelodysplasies (GFM)
Authors: Lionel Ades, Christian Récher, Julie Lejeune, Aspasia Stamatoullas, Marie Sebert, Jacques Delaunay, Benedicte Samey, Krimo Bouabdallah, Thorsten Braun, Norbert Vey, Sophie Park, Benoit de Renzis, Sylvie Chevret, Pierre Fenaux
Journal: Blood (2015)
Structure and evolution of human and African ape rDNA pseudogenes.
Authors: E Brownell, M Krystal, N Arnheim
Journal: Molecular Biology and Evolution (1984)

We discuss the evolutionary significance of four aberrant 18S rDNA clones that were obtained from human, chimpanzee, and gorilla DNA libraries. We show that these clones carry representatives of a small 18S rDNA pseudogene family that arose in a common ancestor of these species. Aspects of their structure and phylogenetic distribution suggest that the 18S pseudogenes no longer interact genetically with normal ribosomal genes and therefore may not be linked to nucleolus organizer regions.
Compliance of adjuvant chemotherapy in non-small cell lung cancer (NSCLC); No longer an issue
Authors: A. Aljubran, N. Leighl, M. Pintilie, R. Feld, R. Burkes, F. Shepherd
Journal: Journal of Clinical Oncology (2006)

7154 Background: Poor compliance has been a common feature in clinical trials of adjuvant chemotherapy for NSCLC with only 48%-69% of patients completing all planned cycles. This may have been due to lack of perceived benefit by patients and physicians and toxicity of the regimens employed. We retrospectively evaluated compliance and toxicity of platinum-based chemotherapy in the two years following the recent reports of successful adjuvant chemotherapy trials for NSCLC. Methods: Following institutional ethics approval, patients who received adjuvant chemotherapy after complete resection of NSCLC between May 2003 and May 2005 were analyzed retrospectively. Patients were identified using an institutional cancer registry. Patient demographics, ECOG status, stage, pathologic subtype and type of surgery were recorded. The number of chemotherapy cycles, delays, dose reductions and change of chemotherapy were all reported. Results: A total of 50 patients were identified. The median age was 62. 38% were stage I, 18% stage II, 30% stage III and 14% had multiple primary tumors of variable stages. 20% were ECOG PS2 and the rest ECOG 0–1. Only 12% had undergone pnemonectomy. 41 patients (82%) started cisplatin /vinorelbine (3 switched to carboplatin because of nephrotoxicity, and one switched to carboplatin/paclitaxel because of fatigue and vomiting). 3 patients received other cisplatin-based combinations. 6 received carboplatin-based treatment (one because of advanced age, one because of cardiac dysfunction and 4 because of preexisting neuropathy). 80% completed all treatment. 40% required dose reduction. 58% required delays in treatment. 6 events of febrile neutropenia were reported in 5 patients. 7 patients required admission. There were no toxic deaths. Multivariate analysis showed no effect of age, gender, extent of surgery or ECOG status on compliance, need for treatment modification or toxicity. Conclusions: Compared to historical trials, adjuvant platinum-based chemotherapy for resected NSCLC is well tolerated and is now accepted by patients and physicians with a high degree of compliance. No significant financial relationships to disclose.
The Health and Turnover of Missionaries
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Doctors were previously the leading practitioners of secrecy
Authors: V. Rippere
Journal: BMJ (1995)

EDITOR,—Naomi Craft asks for further examples of secrecy surrounding health and the NHS in Britain.1 May I nominate the Access to Medical Reports Act 1988 (exemptions, section 7, paragraph 1)2 and the Access to Health Records Act 1990 (section 5, paragraphs 1 (a) (i) and (b))3? But these …
The efficacy of acupressure bands in reducing radiation therapy-induced nausea is enhanced when combined with expectancy enhancing information
Authors: J. A. Roscoe, G. R. Morrow, J. T. Hickok, K. M. Mustian, R. Brasacchio, M. Ling, Y. Chen, P. Okunieff
Journal: Journal of Clinical Oncology (2005)

8158 Background: Mounting evidence suggests that patients’ expectancies relating to nausea development are significant predictors of, and likely, contributing factors to treatment-related nausea. Expectancy is also theorized to be the primary factor accounting for efficacy of alternative therapies such as acupressure bands. Methods: Patients with nausea from radiation therapy were randomized to either standard care (Arm 1), standard care plus acupressure bands plus a handout conveying information not intended to enhance efficacy expectations (Arm 2), or standard care plus acupressure bands plus information designed to enhance efficacy expectations (Arm 3). Prior to randomization, patients reported nausea (on a 7-point semantic rating scale, 1 = “not nauseated” to 7 = “extremely nauseated”) during four time periods (evening and night on the day of treatment, and morning and afternoon of the following day). The four nausea reports were then averaged to create a single score. Post-intervention nausea was assessed in a similar fashion. Results: 63 Patients (female = 37, mean age = 53.3 years) provided evaluable data. The 15 patients randomized to Arm 1 had a small (8%) increase in average nausea. The 26 patients randomized to Arm 2, by contrast, had a modest (15%) decrease in average nausea. A much larger (23%) reduction of nausea occurred in the 22 patients randomized to Arm 3. We used analysis of covariance, controlling for gender, to examine the nausea change scores (post intervention nausea minus baseline nausea) among treatment arms. The overall group difference closely approached conventional levels of statistical significance, P < .08, and the linear contrast was statistically significant, P < .03. Estimated marginal means of the change score for the three groups were: Arm 1 = 0.21, Arm 2 = -0.38, Arm 3 = -0.82. Conclusions: Non-pharmacological interventions that positively affect nausea expectancies have the promise of adding substantially to nausea control. Supported by ACS grant RSG-01–071-PBP No significant financial relationships to disclose.
Diagnosis of COPD before cardiac surgery
Authors: Nicholas J. McKeon, Sjane N. Timmins, Heather Stewart, Stephanie T. Yerkovich, James L. McKeon
Journal: European Respiratory Journal (2015)

We recently performed a retrospective study of the utility of respiratory function tests prior to cardiac surgery at our hospital. The study aimed to identify whether an association exists between pre-operative respiratory function tests and post-operative outcomes. The study also aimed to determine how the definition of chronic obstructive pulmonary disease (COPD) by Global Initiative in Chronic Obstructive Lung Disease (GOLD) [1] or by lower limit of normal (LLN) [2] may alter peri-operative management. COPD defined by LLN criteria is a better predictor of death/pneumonia after cardiac surgery than COPD defined by GOLD <http://ow.ly/QvAPn>
Destruction of Syngeneic Tumors by Tuberculin-Stimulated Peritoneal Exudate Cells From Guinea Pigs Immunized to Mycobacterium bovis (Strain BCG)
Authors: Bruce S. Zwilling, Edward J. Leonard, Robert C. Bast, Berton Zbar
Journal: JNCI Journal of the National Cancer Institute (1974)

Peritoneal exudate (PE) cells from BCG-immune strain-2 guinea pigs were cytotoxic for syngeneic hepatoma cells when incubated in the presence of purified protein derivative of tuberculin. Significant tumor cell destruction occurred with as few as 4×105 PE cells incubated with 4×104 target cells. PE cells were separated into a nonadherent or lymphocyte-rich fraction and an adherent or macrophage fraction. The cytotoxicity of the nonadherent fraction was approximately equal to that of the unseparated PE cells from which the fraction was derived. Since the nonadherent subpopulation contained not only lymphocytes but also significant numbers of macrophages, cytotoxicity could have been due to lymphocytes and/or lymphocyte activation of macrophages. No cytotoxic role could be assigned to the adherent macrophage population.
MUC1/HER2/neu peptide-based immunotherapeutic vaccines for breast adenocarcinomas.
Authors: M. S. Block, S. Markovic, D. W. Northfelt, P. Mukherjee, B. A. Pockaj, W. K. Nevala, J. N. Ingle, E. A. Perez, V. Suman, S. J. Gendler
Journal: Journal of Clinical Oncology (2010)

TPS113 Background: Attempts to use vaccines to stimulate effective antitumor immune responses in breast cancer patients have met with mixed success. While phase I/II trials of a HER2 peptide vaccine have shown some promise in prolonging disease-free survival in lymph node- positive resected breast cancer patients, immune responses to existing vaccines are inconsistent. We hypothesized that addition of the toll-like receptor 9 agonist CpG-7909 and the cytokine GM-CSF (sargramostim) to a peptide vaccine for resected breast cancer patients would increase the frequency of vaccine-specific cytotoxic T lymphocytes generated by patients in response to vaccination. We further hypothesized that using three peptides from the breast cancer associated proteins MUC1 (class I) and HER2 (class I and II) would increase vaccine-specific immune responses. Methods: Patients with resected MUC1-positive breast adenocarcinoma who had completed all standard adjuvant therapy are randomized to one of three treatment arms. Patients in Arm A receive the 3-peptide vaccine emulsified with GM-CSF in Montanide ISA-51. Patients in Arm B receive CpG-7909 in the vaccine emulsion. Patients in Arm C receive both GM-CSF and CpG-7909. Patients in all arms are vaccinated subcutaneously with the peptide-adjuvant emulsion every four weeks for six months, then observed for an additional 18 months. Vaccine immune responses are monitored by staining peripheral blood samples with MHC tetramers containing the peptides of interest. Additionally, changes in multiple plasma cytokines are monitored by multiplex quantification, and changes in peripheral blood immune cell subsets are monitored by flow cytometry. Thus far, 38 of a planned 45 patients have been enrolled. This study was Funded by the DOD Breast Cancer Research Program DAMD 17-01-0318. No significant financial relationships to disclose.
Eltrombopag for the Management of Thrombocytopenia Associated with Tyrosine Kinase Therapy in Patients with Chronic Myeloid Leukemia and Myelofibrosis
Authors: Abdallah Abou Zahr, Jorge E. Cortes, Srdan Verstovsek, Jairo Matthews, Nitin Jain, Elias J. Jabbour, Guillermo Garcia-Manero, Michael Andreef, Kiran Naqvi, Hagop M. Kantarjian, Gautam Borthakur
Journal: Blood (2016)